[{"from": "human", "value": "Describe this molecule. [C][O][C][C][O][C][C][Branch2][Ring2][Branch1][C][O][C][C][C][N][C][=Branch1][C][=O][C][C][N][C][=Branch1][C][=O][C][C][Branch1][Branch1][C][Ring1][=Branch1][=O][S][C][C@@H1][Branch1][=Branch1][C][=Branch1][C][=O][O][N][O][C][C][O][C]"}, {"from": "gpt", "value": "The molecule is a longer-acting Factor VIII therapy formulated with polyethylene glycol (PEG) to reduce the number of infusions necessary to prevent bleeds in patients diagnosed with Haemophilia A. This product has been engineered by Bayer and a biological license application has been filed with the FDA in August 2017 and FDA approved in August 2018."}]